Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Fusion AntibodiesLSE:FAB 26 Cash Ratio is 0.33 as of Sep. 2025, which is 80% below its 10-year median of 1.63. GuruFocus rates LSE:FAB with a GF Score™ of 26/100 and a GF Value™ of £0.04 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 1,355 Biotechnology companies, Fusion Antibodies ranks worse than 86.86% on this metric.
Fusion Antibodies has a Cash Ratio of 0.33. It indicates that there are more current liabilities than Cash, Cash Equivalents, Marketable Securities, and the company does not have sufficient cash on hand to pay off its short-term debt.
The historical rank and industry rank for Fusion Antibodies's Cash Ratio or its related term are showing as below:
LSE:FAB'
s Cash Ratio Range Over the Past 10 Years
Min: 0.22 Med: 1.63 Max: 7.88
Current: 0.33
During the past 11 years, Fusion Antibodies's highest Cash Ratio was 7.88. The lowest was 0.22. And the median was 1.63.
LSE:FAB's Cash Ratio is ranked worse than 86.86% of 1355
companies
in the Biotechnology industry
Industry Median: 2.96
vs LSE:FAB: 0.33
Fusion Antibodies (LSE:FAB) Cash Ratio Explanation
The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.
The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.
In general, the higher the cash ratio, the better the company's liquidity position.
Fusion Antibodies Cash Ratio Related Terms
Fusion Antibodies Cash Ratio Historical Data
* Premium members only.
The historical data trend for Fusion Antibodies's Cash Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LSE:FAB vs VRTX, REGN, RVMD: Cash Ratio Comparison
For the Biotechnology subindustry, Fusion Antibodies's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Fusion Antibodies Cash Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Fusion Antibodies's Cash Ratio distribution charts can be found below:
* The bar in red indicates where Fusion Antibodies's Cash Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Fusion Antibodies (LSE:FAB) has a Cash Ratio of 0.33 as of Sep. 2025. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Fusion Antibodies and its competitors. This is 80% below median its historical median of 1.63. Over the past decade, Fusion Antibodies' Cash Ratio has ranged from 0.22 to 7.88. According to the industry distribution chart, Fusion Antibodies ranks #1177 out of 1355 companies in the Biotechnology industry, placing it in the top 86.9%.
Is Fusion Antibodies' Cash Ratio too high?
Fusion Antibodies' current Cash Ratio of 0.33 is 80% below median its 10-year median of 1.63. Over the past 10 years, this metric has ranged from a low of 0.22 to a high of 7.88. The Biotechnology industry median Cash Ratio is 2.96. Fusion Antibodies' value of 0.33 is 88.9% below this industry median. Based on the distribution chart, Fusion Antibodies ranks #1177 out of 1355 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Fusion Antibodies has a GF Score™ of 26/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Fusion Antibodies' Cash Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Fusion Antibodies ranks #1177 out of 1355 companies for Cash Ratio. This places Fusion Antibodies in the lower half of its industry. The industry median Cash Ratio is 2.96. Fusion Antibodies' value of 0.33 is 88.9% below this benchmark. Historically, Fusion Antibodies' own Cash Ratio has ranged from 0.22 to 7.88 over the past decade. While the company's 10-year median is 1.63 vs. the industry median of 2.96, Fusion Antibodies has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Ratio for a Biotechnology company?
The median Cash Ratio among Biotechnology companies is 2.96, based on 1,355 companies in the industry. Companies in the top quartile (top 25%) have a Cash Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cash Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Fusion Antibodies's current Cash Ratio of 0.33 is 88.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Ratio mean?
A high Cash Ratio can signal that a stock is expensive relative to its fundamentals. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Fusion Antibodies and its competitors. For the Biotechnology industry, the median Cash Ratio is 2.96 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Fusion Antibodies's current Cash Ratio is 0.33, which is 80% below median its own 10-year median of 1.63. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Fusion Antibodies stock overvalued right now?
Based on GuruFocus' analysis, Fusion Antibodies (LSE:FAB) is currently considered Significantly Overvalued. The stock's GF Value™ is £0.04, compared to a current price of £0.10 — trading 156.3% above its estimated fair value. The current Cash Ratio is 0.33, which is 80% below median its 10-year median of 1.63 and 88.9% below the Biotechnology industry median of 2.96. Fusion Antibodies' overall GF Score™ is 26/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Ratio calculated?
Cash Ratio is calculated from a company's financial statements. For Fusion Antibodies (LSE:FAB), the current Cash Ratio is 0.33 as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Fusion Antibodies (LSE:FAB) Overvalued in 2026?
Based on GuruFocus' analysis, Fusion Antibodies stock appears to be overvalued.
The current stock price of £0.10 is trading 156.3% above its estimated GF Value™ of £0.04.
GuruFocus considers Fusion Antibodies to be Significantly Overvalued.
Key valuation signals for LSE:FAB:
Cash Ratio: 0.33 (80% below median its 10-year median of 1.63)
GF Value™: £0.04 vs. price of £0.10 (156.3% above fair value)
Industry Position: 88.9% below the Biotechnology median (#1177 of 1355)
No single metric tells the full story. See the LSE:FAB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Fusion Antibodies PLC is a Contract Research Organisation (CRO) providing antibody identification, engineering, and expression services for the discovery and development of antibodies for human and veterinary therapeutics, as well as for diagnostics. Its customers are pharmaceutical, biotech, veterinary, diagnostic, and life science research companies. The company's three core service areas include: Discovery (identification, screening, and sequencing of novel antibodies); Engineering (optimising the performance of antibodies); and Supply (production and purification of antibodies for further development). Geographically company generates the majority of its revenue from North America and the Rest of the World, followed by the United Kingdom and the Rest of Europe.
26GF Score
Get the complete analysis for LSE:FAB
Cash Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LSE:FAB has been successfully added to your 
